| |
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk, and addressing the specific drug supply challenges commonly associated with complex trial designs. Register now.
|
|
Today's Big NewsJan 30, 2023 |
|
Thursday, Feb 16, 2023 | 2:00pm ET During this session, NetApp will explore how data is leveraged in Life Sciences to create a data fabric strategy that’s aligned to your business. This includes how to detailing each cycle of the data foundation for data governance and quality, data accessibility, data platforms, data as a service, data as a business, predictive intelligence, optimizing how solutions are managed across the data lifecycle, and more. Register now.
|
|
| By Fraiser Kansteiner Citing the evolution of India's healthcare scene during the COVID-19 pandemic, a spokesperson for Sanofi in India told Fierce Pharma that “some activities” at its Medchal and Muppireddypally sites near the city of Hyderabad “are no longer viable.” As a result, Sanofi is offering a voluntary retirement scheme to all staffers at the production facilities. The move could affect some 800 staffers, Reuters reports. |
|
|
|
By James Waldron,Annalee Armstrong,Nick Paul Taylor After a slow 2022, will we see a return to form for biopharma M&A? And, if so, which biotechs does Big Pharma have in its sight? Here are our predictions. |
By Robert King Two senators reintroduced legislation that would install several reforms to PBM practices and a probe from the FTC, signaling that a renewed fight is in the offing for the industry. |
By Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner,Angus Liu,Zoey Becker Heading into 2022, top drugmakers had $1.7 trillion in dealmaking firepower, fueling expectations among analysts that the industry was due for a gangbusters M&A year. Well, that didn’t quite pan out. |
|
Tuesday, Feb 28, 2023 | 11:00am ET The heavy lifting for the pharmaceutical industry to comply with the November 2023 DSCSA go-live date is still ongoing. One item now finalized is to ensure that the required data exchange through the supply chain is only done with trusted, authorized, and registered trading partners. Join us for this discussion to stay up-to-date on this important legislation and be prepared for compliance. Register now.
|
|
By Andrea Park Another 6,000 jobs are on the chopping block at Philips as the devicemaker continues to grapple with the negative impacts of a still-suffocated supply chain, the ongoing recall of 5.5 million of its respiratory devices and a handful of other global issues. |
By Gabrielle Masson Though medicines designed to treat psychiatric conditions have a lower chance of succeeding in drug development than other disease areas, biopharma’s pipeline currently boasts at least 163 medicines targeting mental illness. |
By Andrea Park A recall of nearly 600 controllers used with LivaNova’s LifeSparc cardiac life support system has received its second Class I label from the FDA—this time, for a software update that aims to fix the issue that originally sparked the recall. |
By Dave Muoio The five-year commitment will expand the work of Kaiser Permanente's Center for Gun Violence Research and Education, which launched last summer. Leaders at the integrated system said the work has already yielded promising interventions that they hope to expand and scale with community partners. |
By Zoey Becker Working to grow the reach of its sickle cell disease medicine Adakveo, Novartis has more than just Pfizer's Oxbryta to worry about. The drug couldn't beat out placebo in a phase 3 trial, prompting the European Medicines Agency to review the med's authorized use. |
By Max Bayer The regulatory sprint toward the first FDA-approved RSV vaccine in older adults continues apace, with Moderna tacking breakthrough designation onto its candidate. The MRNA company's announcement follows competitive phase 3 data released earlier this month, rivaling similar readouts from GSK and Pfizer. |
By Conor Hale For 2022, GE HealthCare collected $18.3 billion in revenue, compared to about $17.6 billion the year before. |
By Fraiser Kansteiner Amgen is cutting around 300 jobs in the U.S.—mainly along commercial lines—a company spokesperson said in an email confirming “recently announced organizational changes.” |
By Heather Landi A new tech startup wants to disrupt the clinical trial process and landed $203 million to help scale up its technology. Paradigm, a clinical trial data and patient-matching platform, aims to open up access to research to boost patient recruitment and speed up drug development. |
Fierce podcastsDon't miss an episode |
| | In this week's episode of "Podnosis," we take you inside Fierce's JPM Week event. Listen in on snippets from a panel on what big retailers have to gain by moving into healthcare. And hear from Ramita Tandon about Walgreens' strategy around drug development. |
|
|---|
|
|
|
The global demand for biologics is projected to increase considerably by 2030, but the challenges, risks, and costs are also growing. For pharma companies looking to bring a new biologic to market, meeting clinical trial milestones can be difficult. To access important insights, download this executive summary now.
|
|
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
